A Phase II, Open-label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant
Research Grant
Administered By
Medicine, Medical Oncology
Awarded By
Fred Hutchinson Cancer Research Center
Start Date
September 1, 2015
End Date
August 31, 2017
Administered By
Medicine, Medical Oncology
Awarded By
Fred Hutchinson Cancer Research Center
Start Date
September 1, 2015
End Date
August 31, 2017